Freyr provides clinical trial auditing and monitoring services for both the clinical and bio-analytical phases of the Bioequivalence (BE) studies, Bioavailability (BA) studies, Clinical SOP preparation and review as per health authority regulations.
Facing issue in account approval? email us at info@ipt.pw
FREE SEO TOOLS to Explore
Freyr provides clinical labeling services to Innovative pharmaceutical companies during creation & review of Investigational brochure (IB), Target Labeling (TL), DCDS, FDA Target Product Profile (TPP), EU-draft SmPC during Drug Development Process.
Freyr provides Regulatory Affairs services to Innovator medicine product companies during NDS process with Health Canada, starting from pre-NDS meetings to submission of NDS/Market Notification and further Life Cycle Management (LCM) activities.
Freyr provides Regulatory Affairs services to the Innovator medicine companies during NDA filing process, starting from pre-NDA meetings to NDA submission and further life cycle management of the medicinal Product.
Freyr provides Regulatory Affairs service support to the Innovator medicine companies during IND filing process, starting from pre-IND meetings to IND submission and further to regulatory compliance & maintenance.
Freyr provides Regulatory Affairs services in handling submission of CTA applications/Investigational Medicinal Product Dossier (IMPD) as per EU requirements for different types of medicinal products like New drugs, Recombinant Protein Products, Vaccines, Stem Cell-Based Products etc.
Freyr provides Regulatory Affairs services during planning, preparation and submission of Clinical Trail Application to comply with Health Authority Requirements.
Freyr provides end-to-end Regulatory Affairs services to the Biologics/Biosimilar product companies during BLA submission process, starting from pre-BLA/BPD meetings to further Life Cycle Management (LCM) of the various biological products.
Freyr is a Strategic Regulatory partner providing end-to-end Regulatory solutions and services to Innovator pharma companies during their innovator drug development process.
Freyr provides End-to-End Regulatory Services in Malaysia to the pharmaceuticals, Medical Device, Food Supplements, and Cosmetic Companies to comply with NPRA Regulations.
Freyr acts as a Swiss Authorized Representative(CH-REP) on behalf of foreign medical device manufacturers during registration and compliant market entry of their products as per Swissmedic Regulations.
Freyr provides regulatory services and solutions in Mexico to comply with COFEPRIS for pharma, medical device, cosmetics and food supplement manufacturer companies.
Freyr provides Regulatory Software, Automation and Digital Transformation Solutions to support Global Lifesciences companies.
Freyr provides end to end regulatory support that span across the Covid-19 development lifecycle, marketing authorization, submission of Vaccine BLA, registration, lifecycle management ofvaccine and their regulatory needs.
Freyr supports life science companies during Patient Support Applications, Pharmaceutical Press Releases, pharma advertising and avoid the issues of Prescription Drug Promotion (OPDP)
Freyr provides regulatory service in Canada to Generic medicine manufacturers/ANDS holders for preparation, review, and submission of Abbreviated New Drug Submissions (ANDS) as per Health Canada requirements.
Freyr helps Generic pharma manufacturers/ANDS holders in Health Canada (HC) interactions which include discussing and clarification of potential risks and issues related to their ANDS applications for fast approvals of generics drug products.
Freyr provides regulatory support in ANDS change control evaluation/assessment, post-approval submission strategy and preparation of change-related submission packages as per Health Canada requirements
Freyr provides regulatory support in managing and updating the Drug Master File (DMF) as per Health Canada guidelines and helps in Master file submissions in eCTD format.
Freyr provides regulatory services in Canada to Generic medicine manufacturers/ANDS holders in regulatory submission strategies for submission timelines, documents required for submission, approval process and registering generic medicine as per Health Canada requirements